ECSP055855A - INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO - Google Patents

INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO

Info

Publication number
ECSP055855A
ECSP055855A EC2005005855A ECSP055855A ECSP055855A EC SP055855 A ECSP055855 A EC SP055855A EC 2005005855 A EC2005005855 A EC 2005005855A EC SP055855 A ECSP055855 A EC SP055855A EC SP055855 A ECSP055855 A EC SP055855A
Authority
EC
Ecuador
Prior art keywords
salt
tiotropio
salmeterolxinafoato
drugs containing
inhalation powder
Prior art date
Application number
EC2005005855A
Other languages
Spanish (es)
Inventor
Michael Trunk
Peter Sieger
Mareke Hartig
Michael Walz
Hagen Graebner
Rainer Soyka
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP055855A publication Critical patent/ECSP055855A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a preparaciones en polvo para inhalación que contienen una sal de tiotropio y salmeterolxinafoato, a procedimientos para su preparación, así como a su uso para la preparación de un medicamento para el tratamiento de enfermedades de las vías respiratorias, en especial para el tratamiento de EPOC (= enfermedad pulmonar obstructiva crónica) y asmaThe invention relates to powder preparations for inhalation containing a tiotropium salt and salmeterolxinafoate, to methods for its preparation, as well as to its use for the preparation of a medicament for the treatment of respiratory tract diseases, especially for the COPD treatment (= chronic obstructive pulmonary disease) and asthma

EC2005005855A 2002-12-20 2005-06-15 INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO ECSP055855A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20

Publications (1)

Publication Number Publication Date
ECSP055855A true ECSP055855A (en) 2005-11-22

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005855A ECSP055855A (en) 2002-12-20 2005-06-15 INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO

Country Status (21)

Country Link
EP (1) EP1581198A1 (en)
JP (1) JP2006516135A (en)
KR (1) KR20050086930A (en)
CN (1) CN1728988B (en)
AU (1) AU2003288226B2 (en)
BR (1) BR0317443A (en)
CA (1) CA2510779A1 (en)
DE (1) DE10351663A1 (en)
EA (1) EA010588B1 (en)
EC (1) ECSP055855A (en)
FR (1) FR2848849B1 (en)
HR (1) HRP20050570A2 (en)
IT (1) ITMI20032473A1 (en)
MX (1) MXPA05006519A (en)
NO (1) NO20053548L (en)
NZ (1) NZ541303A (en)
PL (1) PL376231A1 (en)
RS (1) RS20050484A (en)
UA (1) UA83813C2 (en)
WO (1) WO2004058233A1 (en)
ZA (1) ZA200503692B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
JP4342426B2 (en) * 2004-11-24 2009-10-14 科研製薬株式会社 Itraconazole formulation for oral administration
EP1959942A1 (en) * 2005-08-06 2008-08-27 Boehringer Ingelheim International GmbH Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
CN102731494A (en) * 2005-12-19 2012-10-17 西科尔公司 Novel forms of tiotropium bromide and processes for preparation thereof
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
DE102007036411A1 (en) * 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg powder inhaler
PE20090907A1 (en) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
KR20240090632A (en) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN103781788B (en) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 Quinazoline, its preparation and the purposes in pharmaceutical composition thereof being substituted
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (en) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptin, a xanthine derivative as a dpp-4 inhibitor, for use in the treatment of SIRS and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
KR101748796B1 (en) * 2015-09-30 2017-06-19 한미약품 주식회사 Inhalation capsule with enhanced delivery rate of active ingredients
KR102391564B1 (en) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 Combination of Linagliptin and Metformin
CA3119145A1 (en) 2018-11-13 2020-05-22 Cocrystal Pharma, Inc. Formulations comprising 3-(2-(5-chloro-1h-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoro-7h-pyrrolo[2,3-d]pyrimid-7-yl)bicyclo[2.2.2]octane-2-carboxylic acid for the treatment of influenza

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1056974C (en) * 1992-02-11 2000-10-04 格拉克索公司 Drug material suitable for micronisation
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (en) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts
DE10104367A1 (en) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Medicinal compositions containing betamimetics with fewer side effects
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
EP1416990A1 (en) * 2001-08-09 2004-05-12 Glaxo Group Limited Inhalation device with a pharmaceutical composition
WO2003024452A1 (en) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel medicaments for inhalation

Also Published As

Publication number Publication date
CN1728988A (en) 2006-02-01
EA200500902A1 (en) 2006-02-24
ITMI20032473A1 (en) 2004-06-21
JP2006516135A (en) 2006-06-22
ZA200503692B (en) 2006-10-25
FR2848849A1 (en) 2004-06-25
AU2003288226A1 (en) 2004-07-22
MXPA05006519A (en) 2005-08-26
WO2004058233A1 (en) 2004-07-15
BR0317443A (en) 2005-11-16
HRP20050570A2 (en) 2006-07-31
EA010588B1 (en) 2008-10-30
CA2510779A1 (en) 2004-07-15
NO20053548L (en) 2005-09-02
PL376231A1 (en) 2005-12-27
AU2003288226B2 (en) 2010-01-07
CN1728988B (en) 2010-04-28
FR2848849B1 (en) 2007-01-05
UA83813C2 (en) 2008-08-26
KR20050086930A (en) 2005-08-30
NZ541303A (en) 2008-11-28
RS20050484A (en) 2007-11-15
EP1581198A1 (en) 2005-10-05
DE10351663A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
ECSP055855A (en) INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO
ECSP024268A (en) NEW POWDER FOR INHALATION CONTAINING TIOTROPY
ECSP066544A (en) NEW TIOTROPE SALTS, PROCEDURES FOR PREPARATION, AS WELL AS MEDICINAL FORMULATIONS CONTAINING THEM
UY31235A1 (en) NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT
ATE421325T1 (en) COMBINATION OF METHYLXANTHINE COMPOUNDS AND STEROIDS FOR THE TREATMENT OF CHRONIC RESPIRATORY DISEASES
MEP30108A (en) Formoterol superfine formulation
CY1114157T1 (en) TYPES OF SILVER, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL CONTAINERS
EA201201397A1 (en) INHALER CONTAINING DISTRIBUTED GLISTER PACKING
CY1108420T1 (en) STANDARD TYPOTROPIC POWDER FOR INHALATION
NO20051956L (en) Salmeterol superfine formulation
EA201201391A1 (en) INHALER
EA201201393A1 (en) INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER
UY30935A1 (en) COMBINATION: -ANTAGONIST OF THE CHEMIOQUINE RECEIVER 1 (CCR1) -AGONIST OF THE GLUCOCORTICOID RECEPTOR- OPTIONALLY AGONIST B (BETA) 2, - PHARMACEUTICAL COMPOSITION CONTAINING IT - APPLICATIONS.
RU2010120806A (en) MONTELUKAST ACID INHALATION COMPOSITIONS AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID
ATE339951T1 (en) POWDER PREPARATIONS FOR INHALATION
BRPI0415685A (en) tiotropium salts, processes for their production as well as drug formulations containing the same